{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"026-409-769-746-299","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"026-409-769-746-299"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10776,"type":"PATENT","title":"University of Zurich - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":3600,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8246,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"Uni* Zurich\"; \"Univ* Zuerich\"; \"Univ* Zuer*\"; \"Zuer* Uni*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2413
Search Applicants and Owners separately: \"Uni* Zurich\"; \"Univ* Zuerich\"; \"Univ* Zuer*\"; \"Zuer* Uni*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2413
(a) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:26 binds to α-synuclein;\n
(b) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively, and wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:20 binds to α-synuclein;\n
(c) a polynucleotide encoding (i) an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively; and (ii) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively;\n
(d) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:15, wherein the VH when paired with a VL comprising the amino acid sequence set forth in SEQ ID NO:26 binds to α-synuclein;\n
(e) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:20, wherein the VH when paired with a VL comprising the amino acid sequence set forth in SEQ ID NO:26 binds to α-synuclein;\n
(f) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:22, wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:20 binds to α-synuclein;\n
(g) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:26, wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:20 binds to α-synuclein;\n
(h) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:15 and an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:22;\n
(i) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:15 and an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:26;\n
(j) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:20 and an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:22;\n
(k) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:20 and an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:26;\n
(l) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:19;\n
(m) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:21;\n
(n) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:27;\n
(o) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:28;\n
(p) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:19, and an immunoglobulin light chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:27;\n
(q) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising the nucleic acid sequence set forth in SEQ ID NO:19, and an immunoglobulin light chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:28;\n
(r) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:21, and an immunoglobulin light chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:27; and\n
(s) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:21, and an immunoglobulin light chain or a fragment thereof, comprising the nucleic acid sequence set forth in SEQ ID NO:28."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The polynucleotide of claim 1, wherein the heterologous nucleic acid is a regulatory element."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The polynucleotide of claim 2, wherein the regulatory element is a promoter, an enhancer, a ribosome binding site, or a transcription terminator."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The polynucleotide of claim 1, wherein the heterologous nucleic acid is a secretory signal peptide."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The polynucleotide of claim 4, wherein the secretory signal peptide is a mammalian signal peptide."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The polynucleotide of claim 5, wherein the mammalian signal peptide is from tissue plasminogen activator."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["A host cell comprising the polynucleotide of claim 1."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 7, wherein the host cell is a Chinese Hamster Ovary (CHO) cell."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A cDNA comprising a polynucleotide encoding a polypeptide comprising:\n
an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:16, 17, and 18, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:26 binds to α-synuclein; or\n
an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:23, 24, and 25, respectively, and wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:20 binds to α-synuclein."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The cDNA of claim 9, wherein the polypeptide comprises:\n
an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:15;\n
an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:20;\n
an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:22; or\n
an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:26."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["An expression vector comprising a heterologous promoter operably linked to a polynucleotide encoding a polypeptide comprising:\n
an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:16, 17, and 18, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:26 binds to α-synuclein; or\n
an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:23, 24, and 25, respectively, and wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:20 binds to α-synuclein."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 11, wherein the polypeptide comprises:\n
an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:15;\n
an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:20;\n
an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:22; or\n
an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:26."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 11, wherein the expression vector is a plasmid, phage, or virus."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 13, wherein the expression vector is a retrovirus."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 11, wherein the heterologous promoter is a cytomegalovirus, simian virus 40, or retroviral promoter."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 11, wherein the heterologous promoter is the cytomegalovirus immediate early promoter."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 11, wherein the polypeptide comprises a signal peptide."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 17, wherein the signal peptide is a heterologous signal peptide."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["An expression vector comprising:\n
a first polynucleotide encoding a first polypeptide comprising an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising VH complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:16, 17, and 18, respectively; and\n
a second polynucleotide encoding a second polypeptide comprising an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising VL CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:23, 24, and 25, respectively,\n
wherein the immunoglobulin heavy chain or fragment thereof when paired with the immunoglobulin light chain or fragment thereof forms an anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof, and\n
wherein the expression vector is a plasmid, phage, or virus."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 19, wherein the expression vector is a retrovirus."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 19, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:15; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:22."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 19, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:20; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:26."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 22, wherein the first polypeptide comprises a human IgG3 heavy chain constant region and the second polypeptide comprises a human kappa light chain constant region."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 22, wherein the first polypeptide comprises a human IgG1 heavy chain constant region."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The expression vector of claim 19, wherein:\n
the first polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO:21; and\n
the second polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO:27."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["A host cell comprising:\n
a first expression vector comprising a first heterologous promoter operably linked to a first polynucleotide encoding a first polypeptide comprising an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising VH complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:16, 17, and 18, respectively; and\n
a second expression vector comprising a second heterologous promoter operably linked to a second polynucleotide encoding a second polypeptide comprising an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising VL CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:23, 24, and 25, respectively,\n
wherein the immunoglobulin heavy chain or fragment thereof when paired with the immunoglobulin light chain or fragment thereof forms an anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 26, wherein the first heterologous promoter is a cytomegalovirus, simian virus 40, or retroviral promoter and the second heterologous promoter is a cytomegalovirus, simian virus 40, or retroviral promoter."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 26, wherein the first heterologous promoter is the cytomegalovirus immediate early promoter and the second heterologous promoter is the cytomegalovirus immediate early promoter."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 26, wherein the first expression vector is a plasmid, phage, or virus and the second expression vector is a plasmid, phage, or virus."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 29, wherein the first expression vector is a retrovirus and the second expression vector is a retrovirus."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 26, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:15; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:22."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 26, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:20; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:26."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 32, wherein the first polypeptide comprises a human IgG3 heavy chain constant region and the second polypeptide comprises a human kappa light chain constant region."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 32, wherein the first polypeptide comprises a human IgG1 heavy chain constant region."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 26, wherein the host cell is a mammalian host cell."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 26, wherein the host cell is a Chinese Hamster Ovary (CHO) cell, a HEK 293 cell, or a NSO cell."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["A host cell comprising an expression vector comprising:\n
a first polynucleotide encoding a first polypeptide comprising an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising VH complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:16, 17, and 18, respectively; and\n
a second polynucleotide encoding a second polypeptide comprising an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising VL CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:23, 24, and 25, respectively,\n
wherein the immunoglobulin heavy chain or fragment thereof when paired with the immunoglobulin light chain or fragment thereof forms an anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof, and\n
wherein the expression vector is a plasmid, phage, or virus."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 37, wherein the expression vector is a retrovirus."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 37, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:15; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:22."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 37, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:20; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:26."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 40, wherein the first polypeptide comprises a human IgG3 heavy chain constant region and the second polypeptide comprises a human kappa light chain constant region."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 40, wherein the first polypeptide comprises a human IgG1 heavy chain constant region."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 37, wherein the host cell is a mammalian host cell."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["The host cell of claim 37, wherein the host cell is a Chinese Hamster Ovary (CHO) cell, a HEK 293 cell, or a NSO cell."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["A method for preparing an anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof, the method comprising:\n
culturing the host cell of claim 26 in a cell culture; and\n
isolating the anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof from the cell culture."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 45, further comprising formulating the anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof into a sterile pharmaceutical composition suitable for administration to a human subject."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 46, wherein the pharmaceutical composition is suitable for intravenous or subcutaneous administration."],"number":47,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 45, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:15; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:22."],"number":48,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 45, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:20; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:26."],"number":49,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 49, wherein the first polypeptide comprises a human IgG3 heavy chain constant region and the second polypeptide comprises a human kappa light chain constant region."],"number":50,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 49, wherein the first polypeptide comprises a human IgG1 heavy chain constant region."],"number":51,"annotation":false,"title":false,"claim":true},{"lines":["A method for preparing an anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof, the method comprising:\n
culturing the host cell of claim 37 in a cell culture; and\n
isolating the anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof from the cell culture."],"number":52,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 52, further comprising formulating the anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof into a sterile pharmaceutical composition suitable for administration to a human subject."],"number":53,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 53, wherein the pharmaceutical composition is suitable for intravenous or subcutaneous administration."],"number":54,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 52, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:15; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:22."],"number":55,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 52, wherein:\n
the VH consists of the amino acid sequence set forth in SEQ ID NO:20; and\n
the VL consists of the amino acid sequence set forth in SEQ ID NO:26."],"number":56,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 56, wherein the first polypeptide comprises a human IgG3 heavy chain constant region and the second polypeptide comprises a human kappa light chain constant region."],"number":57,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 56, wherein the first polypeptide comprises a human IgG1 heavy chain constant region."],"number":58,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}